InVivo Therapeutics

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The Company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI, and Therapeutic Trails injection program for the treatment of chronic SCI.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2005
Size (employees)
37 (est)
InVivo Therapeutics was founded in 2005 and is headquartered in Cambridge, US

Key People/Management at InVivo Therapeutics

Christopher McNulty

Christopher McNulty

Chief Financial Officer
Kenneth DiPietro

Kenneth DiPietro

Board Director
Richard Toselli

Richard Toselli

Chief Executive Officer and Chief Medical Officer
Pamela Stahl

Pamela Stahl

Chief Commercial Officer
Tamara Joseph

Tamara Joseph

Senior Vice President, General Counsel/Chief Compliance Officer
William D'Agostino

William D'Agostino

Senior Vice President, Operations
Ann Merrifield

Ann Merrifield

Chair of the Board

InVivo Therapeutics Office Locations

InVivo Therapeutics has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square, Building 1400 East, Floor 4
Show all (1)

InVivo Therapeutics Financials and Metrics

InVivo Therapeutics Financials

USD

Net income (Q3, 2017)

(9.4 m)

EBIT (Q3, 2017)

(6.3 m)

Market capitalization (22-Dec-2017)

27.8 m

Cash (30-Sep-2017)

16.4 m
InVivo Therapeutics's current market capitalization is $27.8 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

10.3 m10.1 m12.6 m

General and administrative expense

7.6 m12.3 m11.5 m

Operating expense total

17.8 m22.4 m24.1 m

EBIT

(17.8 m)(22.4 m)(24.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

13.5 m20.2 m21.5 m

Prepaid Expenses

1.1 m184 k451 k

Current Assets

15 m20.7 m33.9 m

PP&E

1.6 m938 k510 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

9.8 m20.9 m17.6 m24.5 m25.1 m22.1 m45.8 m41.6 m37.7 m14.4 m14.3 m16.4 m

Prepaid Expenses

445 k378 k342 k543 k397 k268 k617 k682 k413 k940 k657 k475 k

Current Assets

10.7 m21.6 m18.3 m25.4 m25.9 m22.8 m46.7 m42.7 m38.4 m27.4 m22.9 m18 m

PP&E

2.2 m2 m1.8 m1.4 m1.3 m1.1 m846 k736 k630 k395 k305 k190 k
USDFY, 2014FY, 2015FY, 2016

Net Income

(18.3 m)(33.3 m)(23.4 m)

Depreciation and Amortization

752 k689 k553 k

Accounts Payable

(330 k)(48 k)489 k

Cash From Operating Activities

(15.3 m)(16.3 m)(16.7 m)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.1 m)(8.7 m)(10 m)(15.8 m)(26.3 m)(28.6 m)(6.6 m)(11.8 m)(18 m)(6.4 m)(12.7 m)(22.1 m)

Depreciation and Amortization

195 k378 k568 k178 k352 k527 k146 k284 k417 k135 k264 k387 k

Accounts Payable

(195 k)(307 k)(188 k)224 k384 k228 k(83 k)38 k35 k27 k(133 k)259 k

Cash From Operating Activities

(4.2 m)(7.8 m)(11.1 m)(2.9 m)(7.1 m)(11 m)(4.2 m)(8.3 m)(12.3 m)(6.1 m)(11 m)(15.6 m)
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

InVivo Therapeutics Operating Metrics

FY, 2016

Patents (foreign)

8

Patents (US)

8

Patents Pending

12

Facilities

1
Show all operating metrics

InVivo Therapeutics Market Value History

InVivo Therapeutics's Web-traffic and Trends

InVivo Therapeutics Online and Social Media Presence

InVivo Therapeutics Company Life and Culture

You may also be interested in